newsfilter
← Latest News
ACCESS Newswire·

Ensysce Biosciences Reports Second Quarter 2026 Financial Results and Recent Business Highlights

Acquisition of Cy Biopharma Completed, Adding CY200 for Complex Regional Pain SyndromeUp to $77 million in new funding with the acquisition of Cy BiopharmaCompany to host a Corporate Update Call on Tuesday, August 18,